Jonathan Siegel

1.4k total citations
26 papers, 1.1k citations indexed

About

Jonathan Siegel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Jonathan Siegel has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Jonathan Siegel's work include Cancer Immunotherapy and Biomarkers (6 papers), Occupational and environmental lung diseases (5 papers) and Cancer Research and Treatments (4 papers). Jonathan Siegel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Occupational and environmental lung diseases (5 papers) and Cancer Research and Treatments (4 papers). Jonathan Siegel collaborates with scholars based in United States, Germany and Italy. Jonathan Siegel's co-authors include David M. Berman, Jeffrey S. Weber, David R. Minor, Asim Amin, Steven O’Day, Ilan G. Ron, Hazem Assi, Omid Hamid, Ruggero Ridolfi and Anthony Maraveyas and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Jonathan Siegel

25 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Siegel United States	13	786	355	213	198	119	26	1.1k
Timothy Clay Australia	18	637 0.8×	464 1.3×	177 0.8×	309 1.6×	42 0.4×	84	1.2k
Mastura Md Yusof Malaysia	12	841 1.1×	212 0.6×	360 1.7×	124 0.6×	28 0.2×	32	1.1k
Krista M. Rubin United States	12	717 0.9×	241 0.7×	117 0.5×	176 0.9×	121 1.0×	32	916
Mary Dunn United States	14	519 0.7×	531 1.5×	149 0.7×	200 1.0×	34 0.3×	25	1.1k
Ashley Rosko United States	20	713 0.9×	110 0.3×	81 0.4×	461 2.3×	53 0.4×	122	1.4k
Michael Method United States	18	667 0.8×	159 0.4×	210 1.0×	204 1.0×	158 1.3×	73	1.3k
Zoi Tsourti Greece	15	707 0.9×	192 0.5×	402 1.9×	141 0.7×	58 0.5×	27	1.0k
Annie Wong Australia	11	862 1.1×	208 0.6×	274 1.3×	124 0.6×	106 0.9×	20	1.0k
Shawn F. Johnson United States	8	432 0.5×	304 0.9×	70 0.3×	543 2.7×	55 0.5×	13	1.1k
Isabella C. Glitza United States	19	579 0.7×	114 0.3×	319 1.5×	255 1.3×	78 0.7×	46	953

Countries citing papers authored by Jonathan Siegel

Since Specialization

Citations

This map shows the geographic impact of Jonathan Siegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Siegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Siegel more than expected).

Fields of papers citing papers by Jonathan Siegel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Siegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Siegel. The network helps show where Jonathan Siegel may publish in the future.

Co-authorship network of co-authors of Jonathan Siegel

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Siegel. A scholar is included among the top collaborators of Jonathan Siegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Siegel. Jonathan Siegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cleeland, Charles S., Karen Keating, Brian J. Cuffel, et al.. (2024). Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma. Scientific Reports. 14(1). 14839–14839. 2 indexed citations

Siegel, Jonathan, et al.. (2024). Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance. Pharmaceutical Statistics. 23(5). 709–727. 5 indexed citations

Rugo, Hope S., Catherine Van Poznak, Patrick Neven, et al.. (2023). Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Research and Treatment. 204(2). 249–259. 6 indexed citations

Santin, Alessandro D., Ignace Vergote, Antonio González-Martı́n, et al.. (2022). Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. International Journal of Gynecological Cancer. 33(4). 1–9. 28 indexed citations

Petrylak, Daniel P., Ulka N. Vaishampayan, Celestia S. Higano, et al.. (2021). A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open. 6(2). 100082–100082. 6 indexed citations

Siegel, Jonathan. (2020). The importance of loss functions: A note on the evolution of the Toxicity Probability Interval design. Contemporary Clinical Trials Communications. 22. 100694–100694.

Mendoza, Tito R., Loretta A. Williams, Karen Keating, et al.. (2019). Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Journal of Patient-Reported Outcomes. 3(1). 34–34. 6 indexed citations

Matsubara, Nobuaki, Go Kimura, Hiroji Uemura, et al.. (2019). A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study. International Journal of Clinical Oncology. 25(4). 720–731. 8 indexed citations

Adjei, Alex A., Annette O. Walter, Lisa Cupit, et al.. (2017). Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. Annals of Oncology. 28. v141–v141. 2 indexed citations

10.

Hassan, Raffit, Ross Jennens, Jan P. van Meerbeeck, et al.. (2017). P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma. Journal of Thoracic Oncology. 12(1). S1087–S1088. 1 indexed citations

11.

Hassan, Raffit, John Nemunaitis, Jan P. van Meerbeeck, et al.. (2016). Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). Cancer Research. 76(14_Supplement). CT083–CT083. 2 indexed citations

12.

Weber, Jeffrey S., Asim Amin, David R. Minor, et al.. (2011). Safety and clinical activity of ipilimumab in melanoma patients with brain metastases. Melanoma Research. 21(6). 530–534. 88 indexed citations

13.

Thompson, John A., Omid Hamid, David R. Minor, et al.. (2011). Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma. Journal of Immunotherapy. 35(1). 73–77. 22 indexed citations

14.

Weber, Jeffrey S., John A. Thompson, Omid Hamid, et al.. (2009). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clinical Cancer Research. 15(17). 5591–5598. 460 indexed citations

15.

Berman, David M., Susan Parker, Scott D. Chasalow, et al.. (2008). Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. Journal of Clinical Oncology. 26(15_suppl). 3022–3022. 9 indexed citations

16.

Koenig, Lane, Jonathan Siegel, Henrick J. Harwood, et al.. (2005). Economic benefits of substance abuse treatment: Findings from Cuyahoga County, Ohio. Journal of Substance Abuse Treatment. 28(2). S41–S50. 18 indexed citations

17.

Koenig, Lane, et al.. (2003). Estimating The Mission-Related Costs Of Teaching Hospitals. Health Affairs. 22(6). 112–122. 52 indexed citations

18.

Koenig, Lane, et al.. (2003). Drivers of expenditure growth in outpatient care services.. PubMed. 9 Spec No 1. SP25–33. 9 indexed citations

19.

Koenig, Lane, et al.. (2003). Drivers of healthcare expenditures associated with physician services.. PubMed. 9 Spec No 1. SP34–42. 27 indexed citations

20.

White, Norman M., et al.. (1978). Effects of morphine on one-trial appetitive learning. Life Sciences. 23(19). 1967–1971. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact